Sarepta Therapeutics' Duchenne muscular dystrophy gene therapy update yesterday on four patients through 270 day is a "slight positive" for the stock as no major unexpected red flags emerged, Citi analyst Joel Beatty tells investors in a research note titled "No Bad News from DMD Gene Therapy Data Update Is Good News." Shares of Sarepta closed yesterday down $3.34 to $118.92. However, the analyst says the incremental functional and biomarker data do not add to his conviction because he views these endpoints as inherently difficult to assess in an uncontrolled trial. Nonetheless, Beatty continues to find the previously announced micro-dystrophin expression data as the "most convincing and meaningful piece of data for this agent." He keeps a Buy rating on Sarepta with a $201 price target.